ASCVD in T2D and CVD

Up to 1/3 of people with established cardiovascular disease (CVD) have type 2 diabetes (T2D)¹

9 out of 10 people with established CVD and T2D have atherosclerotic cardiovascular disease (ASCVD)²

ASCVD, including heart attacks and stroke, is responsible for 85% of deaths in people with established CVD³

ASCVD events, including heart attacks and strokes, occur over a decade earlier in people with T2D than those without and will occur with greater severity.^4,5

People with T2D are 2–4 times more likely to have a heart attack

People with T2D are 2–4 times more likely to experience ASCVD events, including heart attacks or strokes than someone without T2D.^6,7

Intervene early to reduce the risk of heart attacks and strokes in your patients with established CVD and T2D.^8-10

American College of Cardiology (ACC) guidelines:⁸

For adults with T2D who have >1 of the following: ASCVD, heart failure, diabetic kidney disease and high risk of ASCVD: The ACC 2020 expert consensus decision pathways recommend starting with a sodium-glucose co-transporter-2 inhibitor (SGLT-2i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) with proven CV benefits depending on patient-specific factors and comorbidities

Discover how ACC guidelines can support heart attack risk reduction >

American Heart Association (AHA)/ American Stroke Association (ASA) guidelines:⁹

For adults with T2D and established ASCVD, including ischaemic stroke: The 2021 AHA/ASA guidelines recommend the addition of glucagon-like peptide-1 receptor agonist (GLP-1 RA)* therapy to metformin, independently of baseline glycated haemoglobin (HbA1c), when prevention of further vascular events is the priority

*Not all GLP-1 RAs demonstrate stroke reduction benefits

Discover how ADA and EASD guidelines can support your treatment choice >

European Society of Cardiology (ESC) guidelines:¹⁰

For adults with T2D and established ASCVD: The 2021 ESC guidelines recommend the use of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or sodium-glucose co-transporter-2 inhibitor (SGLT-2i) with proven outcome benefits to reduce CV and/or cardiorenal outcomes
Post-stroke: GLP-1RA treatment is recommended in post-stroke patients

Discover how ESC guidelines can support you >

In a recent study, only 2 in 10 people with T2D and established CVD, or CV risk factors, received a glucose-lowering agent with proven CV benefit. Treatments include glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter- 2 inhibitors (SGLT-2is).²

Now you can calculate the risk of ASCVD in your patients with T2D.

Clicking this link will lead you to an external website.

Dr. Roopa Mehta, Prof. Carolyn Lam, and Prof. David Cherney explain the importance of looking beyond HbA1c control, to help manage the risk of ASCVD events.

Leverage the HCP-patient discussion guide to aid your patient conversations around ASCVD.

Provide your patients with T2D and CVD a platform that offers fact-checked, curated content about living with these diseases. Refer your patients to this website for guidance on physical and mental wellbeing and tips on how to manage T2D.

Your role is central to ASCVD management in patients with established CVD and T2D.

Lead the way in winning the hearts and minds of people with established CVD and T2D through early intervention and management of ASCVD and in turn reducing the risk of heart attacks and strokes.

ACC, American College of Cardiology; ACE, angiotensin-converting enzyme; AHA, American Heart Association; ASA, American Stroke Association; ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular disease; DDP-4i, dipeptidyl peptidase-4 inhibitor; ESC, European Society of Cardiology; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; MACE, major adverse cardiovascular event; SGLT-2i, sodium-glucose co-transporter-2 inhibitor; T2D, type 2 diabetes.

Buddeke J, et al. Br J Gen Pract. 2019;69(683): e398-e406.

Mosenzon O, et al. Cardiovasc Diabetol. 2021;20:154.

Barquera S, et al. Archives Med Res. 2015;46:328-338.

Low Wang CC, et al. Circulation. 2016;133:2459-2502.

Echouffo-Tcheugui JB, et al. Eur Heart J. 2018;39:2376-2386.

Almdal T, et al. Arch Intern Med. 2004;164:1422-1426.

Fox CS, et al. JAMA. 2004;292:2495-2499.

Das SR, et al. J Am Coll Cardiol. 2020;76:1117-1145.

Kleindorfer DO, et al. Stroke. 2021;52:e364-e467.

10.

Visseren FLJ, et al. Eur Heart J. 2021;42:3227-3337.

11.

Ludwig L. et al. Cardiovasc Diabetol. 2020;19:65.

12.

Kristensen SL, et al. Lancet Diabetes Endocrinol. 2019;7:776–785.

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness, or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.

HQ22CARD00011 August 2022

For healthcare professionals only

American College of Cardiology (ACC) guidelines:8

American Heart Association (AHA)/ American Stroke Association (ASA) guidelines:9

European Society of Cardiology (ESC) guidelines:10

American College of Cardiology (ACC) guidelines:⁸

American Heart Association (AHA)/ American Stroke Association (ASA) guidelines:⁹

European Society of Cardiology (ESC) guidelines:¹⁰